Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia

Completed

Conditions studied: Bronchopulmonary Dysplasia, Prematurity

In brief

The purpose of this study is to identify biological markers that might predict premature infants who are at a higher risk for developing BPD, and to correlate the presence of these markers with infant symptoms and lung function in the first year after discharge from the hospital.

Key facts

Study ID

NCT01748565

Run by

Duke University

People needed

260

Starts

2012-05-01

Expected to finish

2016-08-01

Last updated by the study team

2024-04-12

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Gestational age at birth 23-0/7 to 27-6/7 weeks post-menstrual age

You may not qualify if…

• Are not considered to be viable (decision made not to provide life-saving therapies)
• Have congenital heart disease (not including PDA and hemodynamically insignificant VSD or ASD)
• Have structural abnormalities of the upper airway, lungs or chest wall
• Have other congenital malformations or syndromes that adversely affect life expectancy or cardio-pulmonary development
• Unlikely to return to the clinic for follow-up visits

Where it is running

• Riley Children's Hospital — Indianapolis, Indiana, United States
• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.